The Proof-of-Concept of MBA121, a Tacrine-Ferulic Acid Hybrid, for Alzheimer's Disease Therapy.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
31 Jul 2023
Historique:
received: 19 06 2023
revised: 26 07 2023
accepted: 30 07 2023
medline: 14 8 2023
pubmed: 12 8 2023
entrez: 12 8 2023
Statut: epublish

Résumé

Great effort has been devoted to the synthesis of novel multi-target directed tacrine derivatives in the search of new treatments for Alzheimer's disease (AD). Herein we describe the proof of concept of MBA121, a compound designed as a tacrine-ferulic acid hybrid, and its potential use in the therapy of AD. MBA121 shows good

Identifiants

pubmed: 37569630
pii: ijms241512254
doi: 10.3390/ijms241512254
pmc: PMC10419016
pii:
doi:

Substances chimiques

Tacrine 4VX7YNB537
ferulic acid AVM951ZWST
Butyrylcholinesterase EC 3.1.1.8
Hydrogen Peroxide BBX060AN9V
Amyloid beta-Peptides 0
Cholinesterase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Am J Pathol. 2016 Feb;186(2):375-84
pubmed: 26687817
Neurobiol Aging. 2021 May;101:70-78
pubmed: 33582568
J Neurosci. 2008 Apr 30;28(18):4690-701
pubmed: 18448646
Biomol Eng. 2001 Jun;17(6):157-65
pubmed: 11337275
Elife. 2021 Feb 01;10:
pubmed: 33522485
Eur J Med Chem. 2014 Jun 10;80:543-61
pubmed: 24813882
Front Neurosci. 2019 May 07;13:446
pubmed: 31133787
Hum Mol Genet. 2004 Jan 15;13(2):159-70
pubmed: 14645205
Curr Psychiatry Rep. 2000 Apr;2(2):158-64
pubmed: 11122949
CNS Drugs. 2017 Dec;31(12):1057-1082
pubmed: 29260466
Indian J Pharmacol. 2017 Jan-Feb;49(1):60-64
pubmed: 28458424
PLoS One. 2012;7(2):e31921
pubmed: 22384101
Acta Neurobiol Exp (Wars). 2004;64(1):19-31
pubmed: 15190677
J Med Chem. 2012 May 10;55(9):4309-21
pubmed: 22512543
Pathol Int. 2017 Apr;67(4):185-193
pubmed: 28261941
Curr Neuropharmacol. 2018;16(10):1466-1483
pubmed: 28685671
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189
pubmed: 22229116
Front Neurosci. 2016 May 25;10:205
pubmed: 27252617
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
Front Pharmacol. 2019 Feb 05;10:73
pubmed: 30804787
Neural Regen Res. 2020 Jan;15(1):30-35
pubmed: 31535639
Psychopharmacology (Berl). 2012 Mar;220(1):97-107
pubmed: 21901320
J Alzheimers Dis. 2018;64(s1):S529-S534
pubmed: 29562521
Cells. 2021 Mar 24;10(4):
pubmed: 33804962
EClinicalMedicine. 2022 Jul 22;51:101580
pubmed: 35898316
Int J Mol Sci. 2023 Jan 15;24(2):
pubmed: 36675233
JAMA. 1998 Nov 25;280(20):1777-82
pubmed: 9842955
Stem Cell Reports. 2021 Apr 13;16(4):681-693
pubmed: 33636114
Am J Pathol. 2004 Sep;165(3):987-95
pubmed: 15331422
J Psychopharmacol. 1988 Jan;2(2):67-79
pubmed: 22155841
Molecules. 2016 Oct 11;21(10):
pubmed: 27727187
Neurobiol Aging. 2015 Sep;36(9):2519-32
pubmed: 26089165
CNS Neurol Disord Drug Targets. 2020;19(2):85-93
pubmed: 32056532
Int J Geriatr Psychiatry. 1997 Jan;12(1):7-10
pubmed: 9050416
Bioorg Med Chem Lett. 2008 May 1;18(9):2905-9
pubmed: 18406135
Chem Rec. 2019 May;19(5):927-937
pubmed: 30489012
Bioorg Chem. 2021 Sep;114:105053
pubmed: 34120027
J Neurochem. 2017 Aug;142 Suppl 2:111-121
pubmed: 28791706
J Enzyme Inhib Med Chem. 2018 Dec;33(1):496-506
pubmed: 29405075
Brain. 2017 Mar 1;140(3):826-842
pubmed: 28003243
Pharmacol Biochem Behav. 1991 Aug;39(4):865-71
pubmed: 1763105
J Med Chem. 2008 Dec 25;51(24):7666-9
pubmed: 19053746
Oncotarget. 2018 May 15;9(37):24590-24600
pubmed: 29872490
Curr Neuropharmacol. 2020;18(8):674-695
pubmed: 32172687
Alzheimers Dement. 2021 Mar;17(3):327-406
pubmed: 33756057
Neuron. 1997 Oct;19(4):939-45
pubmed: 9354339
Cell Biol Toxicol. 1998 Oct;14(5):361-73
pubmed: 9808364
F1000Prime Rep. 2015 May 12;7:50
pubmed: 26097723
J Vis Exp. 2011 Jul 26;(53):
pubmed: 21841757
PLoS One. 2013;8(2):e55774
pubmed: 23409038
Acta Neuropathol. 2006 Oct;112(4):389-404
pubmed: 16906426
Curr Med Chem. 2020;27(26):4392-4400
pubmed: 29611473
ChemMedChem. 2015 Mar;10(3):523-39
pubmed: 25537267
J Enzyme Inhib Med Chem. 2018 Dec;33(1):290-302
pubmed: 29278947
Cell. 2016 Feb 11;164(4):603-15
pubmed: 26871627
Neurotherapeutics. 2019 Jul;16(3):543-553
pubmed: 31161490
Front Aging Neurosci. 2021 May 28;13:674318
pubmed: 34122051
Prog Neurobiol. 2017 Apr;151:4-34
pubmed: 26797191
Front Aging Neurosci. 2022 Apr 12;14:870517
pubmed: 35493943
Neural Regen Res. 2019 Mar;14(3):437-440
pubmed: 30539809
Neurology. 1992 Mar;42(3 Pt 1):631-9
pubmed: 1549228
Nat Neurosci. 2017 Oct 26;20(11):1434-1447
pubmed: 29073641
Neurobiol Dis. 2005 Apr;18(3):602-17
pubmed: 15755686
CNS Neurosci Ther. 2012 Nov;18(11):950-1
pubmed: 23106978
Eur J Med Chem. 2019 Mar 15;166:381-389
pubmed: 30739821
Biomed Chromatogr. 2014 Oct;28(10):1352-9
pubmed: 24706520
J Psychiatry Neurosci. 2017 Jan;42(1):59-69
pubmed: 27636528
Lancet. 1976 Dec 25;2(8000):1403
pubmed: 63862
Vasc Health Risk Manag. 2019 Aug 07;15:259-281
pubmed: 31496716

Auteurs

Emelina R Rodríguez-Ruiz (ER)

Neurovascular Research Group, Instituto Cajal (CSIC), Ave. Doctor Arce 37, 28002 Madrid, Spain.

Raquel Herrero-Labrador (R)

Neurovascular Research Group, Instituto Cajal (CSIC), Ave. Doctor Arce 37, 28002 Madrid, Spain.

Ana P Fernández-Fernández (AP)

Neurovascular Research Group, Instituto Cajal (CSIC), Ave. Doctor Arce 37, 28002 Madrid, Spain.

Julia Serrano-Masa (J)

Neurovascular Research Group, Instituto Cajal (CSIC), Ave. Doctor Arce 37, 28002 Madrid, Spain.

José A Martínez-Montero (JA)

Neurovascular Research Group, Instituto Cajal (CSIC), Ave. Doctor Arce 37, 28002 Madrid, Spain.

Daniel González-Nieto (D)

Experimental Neurology Unit, Center for Biomedical Technology (CTB), Universidad Politécnica de Madrid, Campus de Montegancedo S/N, Pozuelo de Alarcón, 28223 Madrid, Spain.

Mayuri Hana-Vaish (M)

UT Southwestern Medical Center, Department of Neurosurgery, School of Medicine, Baylor College of Medicine, Rice University, Houston, TX 77005, USA.

Mohamed Benchekroun (M)

Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive de Besançon, Groupe Chimie Médicinale, Université de Franche-Comté, F-25000 Besançon, France.

Lhassane Ismaili (L)

Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive de Besançon, Groupe Chimie Médicinale, Université de Franche-Comté, F-25000 Besançon, France.

José Marco-Contelles (J)

Laboratory of Medicinal Chemistry, Institute of Organic Chemistry (CSIC), C/Juan de la Cierva, 3, 28006 Madrid, Spain.
Center for Biomedical Network Research on Rare Diseases (CIBERER), CIBER, ISCIII, 28029 Madrid, Spain.

Ricardo Martínez-Murillo (R)

Neurovascular Research Group, Instituto Cajal (CSIC), Ave. Doctor Arce 37, 28002 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH